- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
12/19/14 - 09:02 AM EST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
12/19/14 - 10:46 AM EST
Wednesday's session featured some good moves and technical set-ups, particularly in biotech and technology.
12/18/14 - 01:44 PM EST
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
12/18/14 - 10:01 AM EST
- Tickers in this article:
Companies involved in mining, petroleum exploration, agribusiness, biotechnology and tourism may benefit.
12/17/14 - 03:43 PM EST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
12/17/14 - 09:20 AM EST
Auspex is expected to seek U.S. approval for SD-809 next year.
12/16/14 - 04:06 PM EST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
12/16/14 - 11:20 AM EST
The nominees are in for this year's Worst CEO in Biotech.
12/15/14 - 01:54 PM EST
With 2014 nearly over, the question now becomes which stocks, sectors and strategies billionaire investors will be betting on in 2015. A few predictions.
12/15/14 - 09:27 AM EST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
12/15/14 - 11:49 AM EST
Oil is front and center this month, while Merck is facing some headwinds
12/12/14 - 07:33 AM EST